Health Secretary Defends Policies Before Congress
This week, Health and Human Services Secretary Robert F. Kennedy Jr. faced Congress, defending his department’s initiatives.
Kennedy is under ongoing scrutiny from those skeptical of his “Make America Healthy Again” campaign. He expressed a commitment to collaborate with legislators on health policies aimed at achieving the administration’s objectives.
Spending close to ten hours on Capitol Hill, Kennedy is scheduled for four additional hearings next week.
According to HHS spokesperson Andrew Nixon, “The secretary looks forward to showing Congress our efforts to lower prescription drug prices, clarify healthcare costs for patients, and simplify processes such as prior authorization.”
Kennedy highlighted some early achievements for the department, focusing on addressing chronic illnesses and tackling what he described as the “fraudulent” healthcare system.
He mentioned that HHS has allocated $135 million in rural healthcare funding as part of the One Big Beautiful Bill and has managed to locate 130,000 of the over 400,000 children lost due to the Biden administration’s open-border policies.
The secretary also promised to enhance funding and research for underserved areas, including autism, women’s health, and chronic diseases.
During a hearing with the Ways and Means Committee, Representative Blake Moore from Utah inquired whether Medicare could temporarily cover breakthrough medical devices that have already received FDA approval.
Moore noted the delayed decisions from the Centers for Medicare and Medicaid Services (CMS), which often leave seniors without access to life-saving technologies that are already available.
After the hearing, Moore expressed enthusiasm about potential developments in CMS rulemaking that could accelerate Medicare’s access to innovative medical technologies.
Moore referred to this legislation as stemming from initiatives during Trump’s first term.
He also revealed that he introduced the Insurance Ensuring Patient Access to Critical Breakthroughs Product Act, building on a significant achievement from the previous administration.
In response, Kennedy confirmed an upcoming announcement and expressed readiness to collaborate on the initiative.
Moore emphasized that if a treatment meets the FDA’s requirements for breakthrough designation, Medicare should be able to provide temporary coverage while waiting for a permanent decision from CMS.
He pointed out that most products earning breakthrough status are already available when they receive this classification, yet Medicare delays access to these critical treatments.
“I’m eager to continue working with the administration to ensure seniors access the newest, life-saving treatments quickly,” Moore stated.
Nixon concluded by mentioning efforts to reinforce program integrity by curbing improper payments and addressing issues like waste and fraud, alongside investments in prevention, nutrition, addiction recovery, rare disease treatments, and rural healthcare to enhance patient outcomes nationwide.
